-
Amgen profits rise, next MariTide studies start by mid-year
06 Feb 2025 11:27 GMT
… Deena Beasley (Reuters) - Amgen posted a higher quarterly profit … in after-hours trading. Amgen investors are focused on … studies are conducted properly. Amgen, which has not disclosed … osteoporosis. He expects biosimilar competition sometime in the middle of …
-
Exosomes Skincare Market Set to Witness Significant Growth by 2025-2032: Xollent Biotech, Exosome Sciences, Amgen
06 Feb 2025 07:52 GMT
… analysis. The report also includes competitor and regional analysis, and contemporary … a whole, and the particular competitors faced are also studied in … Sciences
◘ AIVITA Biomedical
◘ Asterand Bioscience
◘ Amgen
This Report includes a company …
-
Pipeline Problems Mar Amgen’s Q4 Beat
05 Feb 2025 16:08 GMT
… business report on Tuesday, Amgen touted revenues that topped analyst … of the obesity space.
Amgen on Tuesday also revealed that … note on Tuesday that Amgen’s Q4 performance “illustrated … entry of biosimilar competition to Prolia. Amgen projected a full- …
-
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
05 Feb 2025 06:24 GMT
Amgen (NASDAQ:AMGN) today announced financial … sales erosion driven by biosimilar competition.
Nplate ® (romiplostim) sales … of recently launched products, competition from other products including … or circumvented by our competitors, or we may fail …
-
Amgen profit beats estimates, next MariTide studies start by mid-year
05 Feb 2025 01:59 GMT
… For full-year 2025, Amgen said it expects adjusted earnings … of exclusivity this year,” Amgen CFO Peter Griffith said, … biosimilar competition sometime in the middle of this year.
Amgen investors … studies are conducted properly.
Amgen, which has not disclosed …
-
Amgen Surpasses Q4 Earnings Forecasts
04 Feb 2025 23:22 GMT
… year.
Amgen's Business Overview
Amgen specializes … .
Quarterly Achievements
Amgen reported impressive progress … operational efficiencies.
Biosimilar competition continues to impose challenges … counterparts. However, Amgen proactively launched its …
-
Colorectal Cancer Therapeutics Market to Surpass USD 22.0 Billion by 2032, Growing at a 6.2% CAGR | SNS Insider
06 Feb 2025 13:55 GMT
… in Targeted Therapies, and Biosimilar Competition Drive Market Expansion
AUSTIN, TX … Ltd.
• Bristol-Myers Squibb Company
• Amgen, Inc.
• Bayer AG
• Sanofi
• Genentech …
-
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same Page
06 Feb 2025 21:59 GMT
… raised the possibility of Amgen launching a biosimilar competitor to Eylea earlier … request for an injunction against Amgen's Pavblu, creating uncertainty … downgraded the stock, warning that Amgen's early entry could …
-
Bristol Myers' stock decline in response to weak guidance is a gift to investors
06 Feb 2025 19:53 GMT
… date: Jan. 17, 2025 Competitors: AbbVie , Pfizer , Amgen , Johnson & Johnson and … Revlimid is seeing increased generic competition, which has contributed to the …
-
Repatha Global Market Report 2025: An In-depth Look at Market Sizes, Growth Trends, and Key Industry Players
06 Feb 2025 17:55 GMT
… repatha market include industry giant Amgen Inc. Their significant presence and … to stay ahead of the competition.
Contact us at:
The Business …